Physician profile
Gary Carlson
NPI 1144280181
$3,140.82
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $192 · 2021: $386 · 2022: $685 · 2023: $889 · 2024: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,618.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $823.83 | 2021-2024 | |
| Abbvie INC. | $492.97 | 2020-2024 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $261.14 | 2019-2024 | Blu-U, Odomzo |
| Galderma Laboratories, L.P. | $209.03 | 2019-2024 | Aklief |
| Leo Pharma INC. | $157.14 | 2020-2024 | Adbry |
| Pfizer INC. | $131.61 | 2023-2024 | |
| Janssen Biotech, INC. | $115.03 | 2021-2023 | Tremfya |
| Arcutis Biotherapeutics, INC. | $101.87 | 2023-2024 | Zoryve |
| Biofrontera INC. | $93.09 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $89.17 | 2022-2024 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $80.41 | 2020-2022 | |
| Incyte Corporation | $79.34 | 2021-2022 | |
| Amgen INC. | $71.85 | 2022-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $70.31 | 2019-2020 | |
| Allergan, INC. | $57.12 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $47.61 | 2019-2023 | Taltz, Olumiant |
| Bayer Healthcare Pharmaceuticals INC. | $42.87 | 2024 | |
| Celgene Corporation | $33.87 | 2019 | |
| Prugen, INC. Pharmaceuticals | $29.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.55 | 2020 | |
| Smith+Nephew, INC. | $23.30 | 2024 | Grafix Pl |
| Kyowa Kirin, INC. | $22.31 | 2023 | Poteligeo |
| Dusa Pharmaceuticals, INC. | $18.16 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $17.99 | 2023 | |
| Almirall LLC | $16.70 | 2021 | |
| Journey Medical Corporation | $16.19 | 2022 | |
| Epi Health, LLC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.